Selvita S.A. stock (PLSEV0000014): Expanding biologics capabilities amid hiring push

Selvita S.A., a Poland-based contract research organization (CRO), recently posted a job opening for a Junior Analytical Specialist – Biologics in Krakow, highlighting its expansion in therapeutic protein characterization services. The role involves LC-MS method development and protein analysis workflows, reflecting demand in the biologics sector. This comes as Selvita operates labs across Europe, serving global pharma clients.

The stock traded at around 30 PLN on the Warsaw Stock Exchange (WSE: SLV) as of early May 2026, according to market data from Warsaw Stock Exchange as of 05/13/2026. US investors can access it via OTC markets or ADRs, providing exposure to Europe's growing CRO market.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Selvita S.A.: core business model

Selvita S.A. provides integrated drug discovery and development services to pharmaceutical and biotech companies worldwide. With labs in Krakow, Poznan, Wroclaw (Poland), Zagreb (Croatia), and an office in Cambridge, UK, it focuses on medicinal chemistry, biology, and computational services. The company reported revenue of 140.5 million PLN for 2023 (full-year results published March 2024), per Selvita investor relations as of 03/2024.

Its business model emphasizes end-to-end solutions from target identification to preclinical candidates, catering to small-molecule and biologics projects. This positions Selvita as a key partner for US firms outsourcing R&D to cut costs in Europe.

Main revenue and product drivers for Selvita S.A.

Key drivers include its Protein Analysis Team, which handles characterization of therapeutic proteins using LC-MS, HPLC, and proteomic assays. The recent job posting for a Junior Analytical Specialist underscores investment in biologics capabilities, vital as global biologics spending hit $300 billion in 2025 per industry reports. Selvita's services support ICH-compliant studies, attracting repeat clients.

Historically, chemistry services formed the bulk of revenue, but biologics and ADME/assay development are growing segments. For US investors, Selvita offers indirect exposure to biotech innovation without direct R&D risks.

Industry trends and competitive position

The CRO market is projected to grow at 8% CAGR through 2030, driven by biologics and AI in drug discovery, according to Statista as of 2025. Selvita competes with players like Charles River and Eurofins but differentiates via Eastern European cost advantages and specialized teams.

Recent hiring signals capacity buildup amid sector tailwinds from increased outsourcing post-pandemic.

Why Selvita S.A. matters for US investors

Listed on the Warsaw exchange, Selvita provides US portfolios with access to Europe's biotech services boom. Many top US pharmas partner with Polish CROs for efficiency, linking Selvita's growth to American drug pipelines and FDA approvals.

Conclusion

Selvita S.A. continues to invest in high-demand areas like biologics analysis, as evidenced by its recent Krakow job opening. With a solid presence in Europe and relevance to global pharma, the company remains positioned in a expanding sector. Investors track its capacity growth and client wins for insights into CRO dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.